172 related articles for article (PubMed ID: 37955615)
1. Lifestyle Walking Intervention for Patients With Heart Failure With Reduced Ejection Fraction: The WATCHFUL Trial.
Vetrovsky T; Siranec M; Frybova T; Gant I; Svobodova I; Linhart A; Parenica J; Miklikova M; Sujakova L; Pospisil D; Pelouch R; Odrazkova D; Parizek P; Precek J; Hutyra M; Taborsky M; Vesely J; Griva M; Semerad M; Bunc V; Hrabcova K; Vojkuvkova A; Svoboda M; Belohlavek J;
Circulation; 2024 Jan; 149(3):177-188. PubMed ID: 37955615
[TBL] [Abstract][Full Text] [Related]
2. Effect of a 6-month pedometer-based walking intervention on functional capacity in patients with chronic heart failure with reduced (HFrEF) and with preserved (HFpEF) ejection fraction: study protocol for two multicenter randomized controlled trials.
Vetrovsky T; Siranec M; Parenica J; Griva M; Stastny J; Precek J; Pelouch R; Bunc V; Linhart A; Belohlavek J
J Transl Med; 2017 Jul; 15(1):153. PubMed ID: 28673328
[TBL] [Abstract][Full Text] [Related]
3. Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial.
Pieske B; Wachter R; Shah SJ; Baldridge A; Szeczoedy P; Ibram G; Shi V; Zhao Z; Cowie MR;
JAMA; 2021 Nov; 326(19):1919-1929. PubMed ID: 34783839
[TBL] [Abstract][Full Text] [Related]
4. Statistical analysis plan for a randomized controlled trial examining pedometer-based walking intervention in patients with heart failure with reduced ejection fraction: the WATCHFUL trial.
Vetrovsky T; Siranec M; Frybova T; Gant I; Semerad M; Miklikova M; Bunc V; Vesely J; Stastny J; Griva M; Precek J; Pelouch R; Parenica J; Jarkovsky J; Belohlavek J
Trials; 2023 Aug; 24(1):539. PubMed ID: 37587489
[TBL] [Abstract][Full Text] [Related]
5. Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial.
Nassif ME; Windsor SL; Tang F; Khariton Y; Husain M; Inzucchi SE; McGuire DK; Pitt B; Scirica BM; Austin B; Drazner MH; Fong MW; Givertz MM; Gordon RA; Jermyn R; Katz SD; Lamba S; Lanfear DE; LaRue SJ; Lindenfeld J; Malone M; Margulies K; Mentz RJ; Mutharasan RK; Pursley M; Umpierrez G; Kosiborod M
Circulation; 2019 Oct; 140(18):1463-1476. PubMed ID: 31524498
[TBL] [Abstract][Full Text] [Related]
6. Effect of Dapagliflozin Versus Placebo on Symptoms and 6-Minute Walk Distance in Patients With Heart Failure: The DETERMINE Randomized Clinical Trials.
McMurray JJV; Docherty KF; de Boer RA; Hammarstedt A; Kitzman DW; Kosiborod MN; Maria Langkilde A; Reicher B; Senni M; Shah SJ; Wilderäng U; Verma S; Solomon SD
Circulation; 2024 Mar; 149(11):825-838. PubMed ID: 38059368
[TBL] [Abstract][Full Text] [Related]
7. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial.
Edelmann F; Wachter R; Schmidt AG; Kraigher-Krainer E; Colantonio C; Kamke W; Duvinage A; Stahrenberg R; Durstewitz K; Löffler M; Düngen HD; Tschöpe C; Herrmann-Lingen C; Halle M; Hasenfuss G; Gelbrich G; Pieske B;
JAMA; 2013 Feb; 309(8):781-91. PubMed ID: 23443441
[TBL] [Abstract][Full Text] [Related]
8. Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF).
Lee MMY; Brooksbank KJM; Wetherall K; Mangion K; Roditi G; Campbell RT; Berry C; Chong V; Coyle L; Docherty KF; Dreisbach JG; Labinjoh C; Lang NN; Lennie V; McConnachie A; Murphy CL; Petrie CJ; Petrie JR; Speirits IA; Sourbron S; Welsh P; Woodward R; Radjenovic A; Mark PB; McMurray JJV; Jhund PS; Petrie MC; Sattar N
Circulation; 2021 Feb; 143(6):516-525. PubMed ID: 33186500
[TBL] [Abstract][Full Text] [Related]
9. Accelerometer-Measured Daily Activity in Heart Failure With Preserved Ejection Fraction: Clinical Correlates and Association With Standard Heart Failure Severity Indices.
Snipelisky D; Kelly J; Levine JA; Koepp GA; Anstrom KJ; McNulty SE; Zakeri R; Felker GM; Hernandez AF; Braunwald E; Redfield MM
Circ Heart Fail; 2017 Jun; 10(6):e003878. PubMed ID: 28588021
[TBL] [Abstract][Full Text] [Related]
10. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.
Redfield MM; Chen HH; Borlaug BA; Semigran MJ; Lee KL; Lewis G; LeWinter MM; Rouleau JL; Bull DA; Mann DL; Deswal A; Stevenson LW; Givertz MM; Ofili EO; O'Connor CM; Felker GM; Goldsmith SR; Bart BA; McNulty SE; Ibarra JC; Lin G; Oh JK; Patel MR; Kim RJ; Tracy RP; Velazquez EJ; Anstrom KJ; Hernandez AF; Mascette AM; Braunwald E;
JAMA; 2013 Mar; 309(12):1268-77. PubMed ID: 23478662
[TBL] [Abstract][Full Text] [Related]
11. Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The VITALITY-HFpEF Randomized Clinical Trial.
Armstrong PW; Lam CSP; Anstrom KJ; Ezekowitz J; Hernandez AF; O'Connor CM; Pieske B; Ponikowski P; Shah SJ; Solomon SD; Voors AA; She L; Vlajnic V; Carvalho F; Bamber L; Blaustein RO; Roessig L; Butler J;
JAMA; 2020 Oct; 324(15):1512-1521. PubMed ID: 33079152
[TBL] [Abstract][Full Text] [Related]
12. Behavioural interventions to promote physical activity in a multiethnic population at high risk of diabetes: PROPELS three-arm RCT.
Khunti K; Griffin S; Brennan A; Dallosso H; Davies M; Eborall H; Edwardson C; Gray L; Hardeman W; Heathcote L; Henson J; Morton K; Pollard D; Sharp S; Sutton S; Troughton J; Yates T
Health Technol Assess; 2021 Dec; 25(77):1-190. PubMed ID: 34995176
[TBL] [Abstract][Full Text] [Related]
13. Association Between Angiotensin Receptor-Neprilysin Inhibition, Cardiovascular Biomarkers, and Cardiac Remodeling in Heart Failure With Reduced Ejection Fraction.
Murphy SP; Prescott MF; Maisel AS; Butler J; Piña IL; Felker GM; Ward JH; Williamson KM; Camacho A; Kandanelly RR; Solomon SD; Januzzi JL
Circ Heart Fail; 2021 Jun; 14(6):e008410. PubMed ID: 33998243
[TBL] [Abstract][Full Text] [Related]
14. Effect of Omecamtiv Mecarbil on Exercise Capacity in Chronic Heart Failure With Reduced Ejection Fraction: The METEORIC-HF Randomized Clinical Trial.
Lewis GD; Voors AA; Cohen-Solal A; Metra M; Whellan DJ; Ezekowitz JA; Böhm M; Teerlink JR; Docherty KF; Lopes RD; Divanji PH; Heitner SB; Kupfer S; Malik FI; Meng L; Wohltman A; Felker GM
JAMA; 2022 Jul; 328(3):259-269. PubMed ID: 35852527
[TBL] [Abstract][Full Text] [Related]
15. The HEART Camp Exercise Intervention Improves Exercise Adherence, Physical Function, and Patient-Reported Outcomes in Adults With Preserved Ejection Fraction Heart Failure.
Alonso WW; Kupzyk KA; Norman JF; Lundgren SW; Fisher A; Lindsey ML; Keteyian SJ; Pozehl BJ
J Card Fail; 2022 Mar; 28(3):431-442. PubMed ID: 34534664
[TBL] [Abstract][Full Text] [Related]
16. Exercise-based cardiac rehabilitation for chronic heart failure: the EXTRAMATCH II individual participant data meta-analysis.
Taylor RS; Walker S; Ciani O; Warren F; Smart NA; Piepoli M; Davos CH
Health Technol Assess; 2019 May; 23(25):1-98. PubMed ID: 31140973
[TBL] [Abstract][Full Text] [Related]
17. Effect of Dapagliflozin on 6-Minute Walk Distance in Heart Failure With Preserved Ejection Fraction: PRESERVED-HF.
Lewis GD; Gosch K; Cohen LP; Nassif ME; Windsor SL; Borlaug BA; Kitzman DW; Shah SJ; Khumri T; Umpierrez G; Lamba S; Sharma K; Khan SS; Kosiborod MN; Sauer AJ
Circ Heart Fail; 2023 Nov; 16(11):e010633. PubMed ID: 37869881
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial.
Butt JH; Adamson C; Docherty KF; de Boer RA; Petrie MC; Inzucchi SE; Kosiborod MN; Maria Langkilde A; Lindholm D; Martinez FA; Bengtsson O; Schou M; O'Meara E; Ponikowski P; Sabatine MS; Sjöstrand M; Solomon SD; Jhund PS; McMurray JJV; Køber L
Circ Heart Fail; 2021 Dec; 14(12):e008837. PubMed ID: 34802253
[TBL] [Abstract][Full Text] [Related]
19. Effect of Personalized Accelerated Pacing on Quality of Life, Physical Activity, and Atrial Fibrillation in Patients With Preclinical and Overt Heart Failure With Preserved Ejection Fraction: The myPACE Randomized Clinical Trial.
Infeld M; Wahlberg K; Cicero J; Plante TB; Meagher S; Novelli A; Habel N; Krishnan AM; Silverman DN; LeWinter MM; Lustgarten DL; Meyer M
JAMA Cardiol; 2023 Mar; 8(3):213-221. PubMed ID: 36723919
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
